IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Bennett C Borer

USPTO Granted Patents = 14

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 31(Granted Patents)


Location History:

  • La Jolla, CA (US) (2002)
  • San Diego, CA (US) (1998 - 2024)

Company Filing History:

goldMedal7 out of 174 
 
Agouron Pharmaceuticals, Inc.
 patents
silverMedal2 out of 1,037 
 
Japan Tobacco Inc.
 patents
bronzeMedal2 out of 21 
 
Effector Therapeutics, Inc.
 patents
4. 1 out of 262 
 
Cancer Research Technology Limited
 patents
5. 1 out of 2 
 
Strategic Enzyme Applications, Inc.
 patents
6. 1 out of 1 
 
Stragegic Enzyme Applications, Inc.
 patent
7. 1 out of 1 
 
Agouron Phramaceuticals, Inc.
 patent
8. 2 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...
14 patents (USPTO):
1. 11952375 - Crystalline forms of Mnk inhibitors (2024-04-09),
2. 11130757 - Crystalline forms of MNK inhibitors (2021-09-28),
3. 9683001 - Process of producing phosphinothricin employing nitrilases (2017-06-20),
4. 8981142 - Process of producing phosphinothricin employing nitrilases (2015-03-17),
5. 7268126 - Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-ce]indol-6-one (2007-09-11),
6. 6472534 - Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors (2002-10-29),
7. 6465661 - Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors (2002-10-15),
8. 6403799 - Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors (2002-06-11),
9. 6392067 - Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors (2002-05-21),
10. 6316625 - Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors (2001-11-13),
11. 6117999 - Methods of making HIV-protease inhibitors and intermediates for making (2000-09-12),
12. 6084107 - Intermediates for making HIV-protease inhibitors (2000-07-04),
13. 5925759 - Methods of making HIV-protease inhibitors and intermediates for making (1999-07-20),
14. 5705647 - Intermediates for making HIV-protease inhibitors (1998-01-06),

Title: An Overview of Inventor Bennett C Borer

Introduction

Bennett C Borer is an esteemed inventor hailing from San Diego, California. With a remarkable portfolio consisting of 14 patents, he has made significant contributions to the field of therapeutic applications, particularly focusing on Mnk inhibitors. His innovative work has the potential to impact various medical treatments, including inflammation and cancer therapies.

Latest Patents

Bennett's latest patents include innovative crystalline forms of Mnk inhibitors. One noteworthy invention describes crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione. These crystalline compounds are identified as effective inhibitors of Mnk and have substantial utility in therapeutic applications. His inventions aim to improve treatment outcomes for various medical conditions, including inflammation and different types of cancers.

Career Highlights

Throughout his career, Bennett C Borer has collaborated with leading pharmaceutical companies, notably Agouron Pharmaceuticals, Inc. and Japan Tobacco Inc. His time in these organizations has allowed him to refine his expertise and contribute to significant advancements in the pharmaceutical industry.

Collaborations

Bennett has worked alongside talented individuals such as Juliette K Busse and Kim F Albizati, fostering a collaborative environment that encourages innovation and problem-solving in the realm of therapeutic applications. These collaborations have proven essential in enhancing the development of his patented inventions.

Conclusion

In conclusion, Bennett C Borer stands out as an influential figure in the realm of inventions related to medicinal chemistry and therapeutic applications. With 14 patents to his name, his innovative contributions, particularly in Mnk inhibitors, are paving the way for improved treatment options for critical health issues. His collaborations and career achievements underscore his commitment to advancing medical science through targeted innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…